InterCure Ltd. regained Nasdaq minimum bid compliance after its ordinary shares recorded a closing bid price of $1.00 per share or greater through September 4. The determination closed the delisting matter, giving investors confirmation that the Nasdaq listing requirement described in the notice had been satisfied.
Key Highlights
- The applicable compliance period ended August 24 under Nasdaq Listing Rule 5810.
- InterCure’s February 25 notification followed a period when its ordinary shares closed below $1.00 per share.
- InterCure regained compliance after its ordinary shares recorded closing bid prices of at least $1.00 per share through September 4.
- Nasdaq confirmed the compliance result on September 8.
InterCure Ltd. (NASDAQ: INCR) regained compliance with Nasdaq’s minimum bid price requirement after its ordinary shares recorded a closing bid price of $1.00 per share or greater through September 4. Nasdaq confirmed the result on September 8 and said the matter was closed.
Nasdaq Confirms $1.00 Bid Compliance
Nasdaq’s Listing Qualifications Department notified InterCure that the requirement under Listing Rule 5450(a)(1) had been met. The determination followed a February 25 notification stating that the ordinary shares had traded below $1.00 per share for a consecutive business-day period. Rule 5810 provided an applicable compliance period ending August 24. On September 8, Nasdaq confirmed that closing bids were at least $1.00 per share from August 24 through September 4.
Delisting Notice Matter Is Closed
The September 1 notice identified a direct listing consequence after InterCure failed to regain compliance within the applicable period. The September 8 determination confirmed that the price condition had been met and that InterCure had regained compliance with Rule 5450(a)(1). Nasdaq’s statement that the matter was closed is the stated resolution to the delisting notice for the ordinary shares.
FAQs
Q: Why did InterCure regain Nasdaq compliance?
A: Nasdaq determined that InterCure’s ordinary shares met the minimum bid price requirement after closing bids reached $1.00 per share or greater through September 4. The matter was closed on September 8.
Q: Is InterCure still facing a Nasdaq minimum bid issue?
A: Nasdaq confirmed that InterCure regained compliance with Listing Rule 5450(a)(1). Nasdaq also said the matter was closed after the ordinary shares met the $1.00 per-share requirement.
Q: Which Nasdaq requirement did InterCure satisfy?
A: Nasdaq’s Listing Qualifications Department determined that InterCure met the minimum bid price requirement under Listing Rule 5450(a)(1). The determination followed the applicable compliance period under Rule 5810.
Q: What was the resolution of the delisting notice?
A: Nasdaq confirmed that InterCure had regained compliance with Rule 5450(a)(1) and stated that the matter was closed. This resolved the delisting notice concerning the ordinary shares.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.